Symbols / MREO
MREO Chart
About
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 63.29M |
| Enterprise Value | 272.03M | Income | -41.57M | Sales | 500.00K |
| Book/sh | 0.29 | Cash/sh | 0.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 36 | IPO | — |
| P/E | — | Forward P/E | -12.59 | PEG | — |
| P/S | 126.57 | P/B | 1.36 | P/C | — |
| EV/EBITDA | -6.04 | EV/Sales | 544.06 | Quick Ratio | 8.35 |
| Current Ratio | 8.71 | Debt/Eq | 0.85 | LT Debt/Eq | — |
| EPS (ttm) | -0.25 | EPS next Y | -0.03 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-25 | ROA | -39.81% |
| ROE | -69.79% | ROIC | — | Gross Margin | 73.40% |
| Oper. Margin | -90.68% | Profit Margin | 0.00% | Shs Outstand | 159.13M |
| Shs Float | 537.96M | Short Float | 11.52% | Short Ratio | 0.50 |
| Short Interest | — | 52W High | 3.05 | 52W Low | 0.20 |
| Beta | 0.26 | Avg Volume | 15.40M | Volume | 1.15M |
| Target Price | $2.65 | Recom | None | Prev Close | $0.40 |
| Price | $0.40 | Change | -1.22% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.65
Mean price target
2. Current target
$0.40
Latest analyst target
3. DCF / Fair value
$-2.28
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.40
Low
$0.50
High
$8.03
Mean
$2.65
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-16 | reit | BTIG | Buy → Buy | $1 |
| 2026-01-13 | main | Needham | Buy → Buy | $3 |
| 2025-12-30 | down | Jefferies | Buy → Hold | $1 |
| 2025-12-29 | main | BTIG | Buy → Buy | $1 |
| 2025-12-29 | down | LifeSci Capital | Outperform → Market Perform | — |
| 2025-12-22 | reit | Needham | Buy → Buy | $5 |
| 2025-12-18 | reit | BTIG | Buy → Buy | $6 |
| 2025-08-25 | main | JP Morgan | Overweight → Overweight | $8 |
| 2025-07-10 | main | Needham | Buy → Buy | $5 |
| 2025-05-13 | reit | Needham | Buy → Buy | $7 |
| 2025-04-09 | reit | Needham | Buy → Buy | $7 |
| 2025-03-27 | init | JP Morgan | — → Overweight | $7 |
| 2025-03-26 | reit | Needham | Buy → Buy | $7 |
| 2025-03-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $7 |
| 2025-01-13 | reit | Needham | Buy → Buy | $7 |
| 2024-12-24 | init | LifeSci Capital | — → Outperform | $10 |
| 2024-12-17 | reit | Needham | Buy → Buy | $7 |
| 2024-12-06 | init | Jefferies | — → Buy | $7 |
| 2024-11-12 | reit | Needham | Buy → Buy | $7 |
| 2024-10-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $7 |
- LEVI & KORSINSKY, LLP: MREO Stock Loss Quantifies Investor Damages Following Phase 3 Trial Disclosure - GlobeNewswire hu, 19 Feb 2026 21
- MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - Morningstar Mon, 09 Feb 2026 08
- Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com Mon, 29 Dec 2025 08
- Brittle bone drug trial falls short on fractures but boosts bone density - Stock Titan Mon, 29 Dec 2025 08
- Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - FinancialContent hu, 19 Feb 2026 14
- Mereo BioPharma Group plc (MREO) Stock Analysis: Exploring a Potential 780% Upside in Biotech Innovation - DirectorsTalk Interviews hu, 08 Jan 2026 08
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo BioPharma Group plc Lawsuit - MREO - marketscreener.com ue, 24 Feb 2026 14
- Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials - Quiver Quantitative ue, 30 Dec 2025 08
- We're Interested To See How Mereo BioPharma Group (NASDAQ:MREO) Uses Its Cash Hoard To Grow - Yahoo Finance Wed, 22 Oct 2025 07
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials - TipRanks Mon, 29 Dec 2025 08
- Rare disease drug maker maps next steps as cash runway to 2027 - Stock Titan Mon, 12 Jan 2026 08
- Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - Morningstar Wed, 18 Feb 2026 23
- Stockholders Who Lost Money Investing in Mereo BioPharma - GlobeNewswire Wed, 18 Feb 2026 19
- Ongoing Mereo BioPharma Group plc (MREO) Investigation: Protect Your Rights - Contact Levi & Korsinsky - TMX Newsfile Mon, 26 Jan 2026 08
- Mereo BioPharma Group Plc (MREO): A Deep Dive Into A Potential 527% Upside In Biotech - DirectorsTalk Interviews hu, 19 Feb 2026 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 16149 | 69477.0 | — | Sale at price 4.22 - 4.47 per share. | LEWICKI JOHN A | Officer | — | 2024-09-13 00:00:00 | D |
| 1 | 30926 | 133051.0 | — | Sale at price 4.22 - 4.47 per share. | SERMON CHARLES E. | General Counsel | — | 2024-09-13 00:00:00 | D |
| 2 | 88657 | 381423.0 | — | Sale at price 4.22 - 4.47 per share. | SCOTS-KNIGHT DENISE | Chief Executive Officer | — | 2024-09-13 00:00:00 | D |
| 3 | 148110 | 637203.0 | — | Sale at price 4.22 - 4.47 per share. | HUGHES-WILSON ALEXANDRA | Officer | — | 2024-09-13 00:00:00 | D |
| 4 | 28286 | 121693.0 | — | Sale at price 4.22 - 4.47 per share. | FOX CHRISTINE ANN | Chief Financial Officer | — | 2024-09-13 00:00:00 | D |
| 5 | 46000 | nan | — | — | LEWICKI JOHN A | Officer | — | 2024-09-11 00:00:00 | D |
| 6 | 65600 | nan | — | — | SERMON CHARLES E. | General Counsel | — | 2024-09-11 00:00:00 | D |
| 7 | 188060 | nan | — | — | SCOTS-KNIGHT DENISE | Chief Executive Officer | — | 2024-09-11 00:00:00 | D |
| 8 | 208333 | 206416.0 | — | Conversion of Exercise of derivative security at price 1.01 - 1.40 per share. | HUGHES-WILSON ALEXANDRA | Officer | — | 2024-09-11 00:00:00 | D |
| 9 | 60000 | nan | — | — | FOX CHRISTINE ANN | Chief Financial Officer | — | 2024-09-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -37.84K | 200.81K | 5.63M |
| TaxRateForCalcs | 0.00 | 0.02 | 0.02 | 0.11 |
| NormalizedEBITDA | -41.59M | -23.95M | -49.88M | -27.42M |
| TotalUnusualItems | 791.00K | -2.10M | 12.01M | 52.90M |
| TotalUnusualItemsExcludingGoodwill | 791.00K | -2.10M | 12.01M | 52.90M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -43.25M | -29.47M | -42.22M | 17.17M |
| ReconciledDepreciation | 1.09M | 1.06M | 889.00K | 866.47K |
| ReconciledCostOfRevenue | 0.00 | 2.57M | -1.15M | 24.17M |
| EBITDA | -40.80M | -26.06M | -37.87M | 25.49M |
| EBIT | -41.88M | -27.12M | -38.76M | 24.62M |
| NetInterestIncome | 1.67M | -750.00K | -3.33M | -5.43M |
| InterestExpense | 1.37M | 2.88M | 4.17M | 5.40M |
| InterestIncome | 3.04M | 2.13M | 840.00K | 1.35K |
| NormalizedIncome | -44.04M | -27.40M | -54.03M | -30.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -43.25M | -29.47M | -42.22M | 17.17M |
| TotalExpenses | 45.72M | 37.14M | 52.70M | 77.47M |
| TotalOperatingIncomeAsReported | -47.36M | -28.42M | -54.43M | -28.26M |
| DilutedAverageShares | 147.92M | 131.89M | 113.99M | 111.06M |
| BasicAverageShares | 147.92M | 131.89M | 113.99M | 105.56M |
| DilutedEPS | -0.30 | -0.20 | -0.36 | -0.34 |
| BasicEPS | -0.30 | -0.20 | -0.36 | 0.13 |
| DilutedNIAvailtoComStockholders | -43.25M | -29.47M | -42.22M | -34.82M |
| AverageDilutionEarnings | 0.00 | -51.99M | ||
| NetIncomeCommonStockholders | -43.25M | -29.47M | -42.22M | 17.17M |
| NetIncome | -43.25M | -29.47M | -42.22M | 17.17M |
| NetIncomeIncludingNoncontrollingInterests | -43.25M | -29.47M | -42.22M | 17.17M |
| NetIncomeContinuousOperations | -43.25M | -29.47M | -42.22M | 17.17M |
| TaxProvision | 0.00 | -532.00K | -718.00K | 2.05M |
| PretaxIncome | -43.25M | -30.00M | -42.94M | 19.22M |
| OtherIncomeExpense | 791.00K | -2.11M | 13.10M | 52.90M |
| OtherNonOperatingIncomeExpenses | -10.00K | 1.09M | ||
| SpecialIncomeCharges | 0.00 | 152.51K | ||
| GainOnSaleOfPPE | 0.00 | 152.51K | ||
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 791.00K | -2.10M | 12.01M | 52.75M |
| NetNonOperatingInterestIncomeExpense | 1.67M | -750.00K | -3.33M | -5.43M |
| TotalOtherFinanceCost | 49.62K | 28.34K | ||
| InterestExpenseNonOperating | 1.37M | 2.88M | 4.17M | 5.40M |
| InterestIncomeNonOperating | 3.04M | 2.13M | 840.00K | 1.35K |
| OperatingIncome | -45.72M | -27.14M | -52.70M | -28.26M |
| OperatingExpense | 45.72M | 34.56M | 53.84M | 53.30M |
| OtherOperatingExpenses | -1.65M | -1.28M | -1.73M | |
| ResearchAndDevelopment | 20.93M | 17.42M | 29.46M | 31.80M |
| SellingGeneralAndAdministration | 26.43M | 18.42M | 26.11M | 21.50M |
| GeneralAndAdministrativeExpense | 26.43M | 18.42M | 26.11M | 21.50M |
| OtherGandA | 26.43M | 18.42M | 26.11M | 21.50M |
| GrossProfit | 0.00 | 7.43M | 1.15M | 25.04M |
| CostOfRevenue | 0.00 | 2.57M | -1.15M | 24.17M |
| TotalRevenue | 0.00 | 10.00M | 0.00 | 49.21M |
| OperatingRevenue | 0.00 | 10.00M | 0.00 | 49.21M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 923.40K | 1.00M | 1.08M | |
| OrdinarySharesNumber | 775.73M | 700.29M | 623.93M | 583.83M |
| ShareIssued | 775.73M | 701.22M | 624.93M | 584.91M |
| TotalDebt | 6.43M | 5.95M | 15.37M | 22.62M |
| TangibleBookValue | 60.33M | 49.45M | 51.40M | 85.62M |
| InvestedCapital | 66.50M | 54.93M | 64.73M | 138.18M |
| WorkingCapital | 60.91M | 54.27M | 50.82M | 117.12M |
| NetTangibleAssets | 60.33M | 49.45M | 51.40M | 85.62M |
| CapitalLeaseObligations | 894.00K | 1.56M | 2.04M | 3.21M |
| CommonStockEquity | 60.97M | 50.54M | 51.40M | 118.77M |
| TotalCapitalization | 60.97M | 54.93M | 51.40M | 138.18M |
| TotalEquityGrossMinorityInterest | 60.97M | 50.54M | 51.40M | 118.77M |
| StockholdersEquity | 60.97M | 50.54M | 51.40M | 118.77M |
| GainsLossesNotAffectingRetainedEarnings | -18.85M | -17.48M | -21.69M | 184.76M |
| OtherEquityAdjustments | -18.85M | -17.48M | -21.69M | 185.22M |
| ForeignCurrencyTranslationAdjustments | -2.17M | -460.23K | ||
| TreasuryStock | 0.00 | 1.23M | 1.33M | 1.54M |
| RetainedEarnings | -462.88M | -419.63M | -404.57M | -400.80M |
| AdditionalPaidInCapital | 539.64M | 486.11M | 476.52M | 333.98M |
| CapitalStock | 3.06M | 2.77M | 2.48M | 2.37M |
| CommonStock | 3.06M | 2.77M | 2.48M | 2.37M |
| TotalLiabilitiesNetMinorityInterest | 15.42M | 15.96M | 26.01M | 51.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.57M | 6.48M | 1.64M | 34.92M |
| OtherNonCurrentLiabilities | 565.00K | 764.00K | 182.00K | 107.97K |
| DerivativeProductLiabilities | 821.00K | 412.00K | 157.00K | 11.25M |
| LongTermDebtAndCapitalLeaseObligation | 187.00K | 5.30M | 1.48M | 21.78M |
| LongTermCapitalLeaseObligation | 187.00K | 906.00K | 1.48M | 2.37M |
| LongTermDebt | 4.39M | 19.41M | ||
| LongTermProvisions | 1.78M | |||
| CurrentLiabilities | 13.85M | 9.49M | 24.38M | 16.93M |
| OtherCurrentLiabilities | 61.00K | 30.00K | 1.35M | 1.71M |
| CurrentDeferredLiabilities | 296.00K | 711.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 6.24M | 652.00K | 13.89M | 839.47K |
| CurrentCapitalLeaseObligation | 707.00K | 652.00K | 564.00K | 839.47K |
| CurrentDebt | 5.54M | 13.33M | ||
| OtherCurrentBorrowings | 5.54M | 13.33M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.00M | 1.62M | 1.86M | |
| CurrentProvisions | 4.82M | 3.78M | ||
| PayablesAndAccruedExpenses | 5.25M | 6.47M | 7.27M | 10.59M |
| CurrentAccruedExpenses | 1.80M | 3.46M | 3.57M | 5.16M |
| Payables | 3.44M | 3.01M | 3.69M | 5.43M |
| OtherPayable | 235.00K | 25.00K | 32.39K | |
| TotalTaxPayable | 770.00K | 662.00K | 202.00K | 2.31M |
| AccountsPayable | 2.44M | 2.35M | 3.49M | 3.08M |
| TotalAssets | 76.39M | 66.50M | 77.41M | 170.62M |
| TotalNonCurrentAssets | 1.63M | 2.74M | 2.22M | 36.57M |
| GoodwillAndOtherIntangibleAssets | 643.00K | 1.09M | 0.00 | 33.15M |
| OtherIntangibleAssets | 1.09M | 24.12M | 33.15M | |
| NetPPE | 984.00K | 1.65M | 2.22M | 3.41M |
| AccumulatedDepreciation | -949.00K | -800.00K | -736.00K | -2.13M |
| GrossPPE | 1.93M | 2.45M | 2.95M | 5.54M |
| Leases | 712.00K | 710.00K | 675.00K | 751.75K |
| OtherProperties | 298.00K | 296.00K | 422.00K | 641.08K |
| MachineryFurnitureEquipment | 196.00K | 199.00K | 190.00K | 233.49K |
| BuildingsAndImprovements | 727.00K | 1.25M | 1.67M | 3.92M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 74.76M | 63.76M | 75.20M | 134.05M |
| OtherCurrentAssets | 129.00K | 340.00K | 1.43M | 3.78M |
| PrepaidAssets | 1.58M | 2.27M | 2.83M | 550.65K |
| Receivables | 3.25M | 3.73M | 2.75M | 2.46M |
| OtherReceivables | 2.79M | 3.13M | 1.57M | 842.17K |
| TaxesReceivable | 464.00K | 599.00K | 1.18M | 1.61M |
| CashCashEquivalentsAndShortTermInvestments | 69.80M | 57.42M | 68.18M | 127.27M |
| CashAndCashEquivalents | 69.80M | 57.42M | 68.18M | 127.27M |
| CashEquivalents | 51.10M | 767.94K | ||
| CashFinancial | 5.23M | 126.50M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.53M | -21.55M | -48.83M | -7.79M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | 0.00 | -3.19M | -1.13M | -933.95K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 47.00M | 11.61M | 0.00 | 105.99M |
| CapitalExpenditure | -699.00K | -419.00K | -13.00K | -722.06K |
| InterestPaidSupplementalData | 21.00K | 884.00K | ||
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 69.80M | 57.42M | 68.18M | 127.27M |
| BeginningCashPosition | 57.42M | 68.18M | 127.40M | 31.67M |
| EffectOfExchangeRateChanges | -233.00K | 2.82M | -12.58M | -1.57M |
| ChangesInCash | 12.61M | -13.58M | -46.63M | 97.16M |
| FinancingCashFlow | 46.15M | 7.97M | 200.00K | 104.80M |
| CashFlowFromContinuingFinancingActivities | 46.15M | 7.97M | 200.00K | 104.80M |
| NetOtherFinancingCharges | -853.00K | -444.00K | 200.00K | -315.82K |
| InterestPaidCFF | 0.00 | 0.00 | ||
| ProceedsFromStockOptionExercised | 0.00 | 62.08K | ||
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 47.00M | 11.61M | 0.00 | 105.99M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 47.00M | 11.61M | 0.00 | 105.99M |
| NetIssuancePaymentsOfDebt | 0.00 | -3.19M | -1.13M | -933.95K |
| NetLongTermDebtIssuance | 0.00 | -3.19M | -1.13M | -933.95K |
| LongTermDebtPayments | 0.00 | -3.19M | -1.13M | -933.95K |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -699.00K | -419.00K | 1.99M | -568.20K |
| CashFlowFromContinuingInvestingActivities | -699.00K | -419.00K | 1.99M | -568.20K |
| NetOtherInvestingChanges | -814.46K | |||
| InterestReceivedCFI | 842.30K | 1.35K | ||
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | ||
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | 0.00 | 0.00 | ||
| NetIntangiblesPurchaseAndSale | -699.00K | -419.00K | 0.00 | 152.51K |
| SaleOfIntangibles | 1.80M | 152.51K | ||
| PurchaseOfIntangibles | -699.00K | -419.00K | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | 1.99M | -722.06K | |
| SaleOfPPE | 0.00 | 2.00M | ||
| PurchaseOfPPE | 0.00 | -13.00K | -722.06K | |
| OperatingCashFlow | -32.83M | -21.13M | -48.82M | -7.07M |
| CashFlowFromContinuingOperatingActivities | -32.83M | -21.13M | -48.82M | -7.07M |
| TaxesRefundPaid | -1.85M | 3.81M | ||
| ChangeInWorkingCapital | -369.00K | -1.59M | -2.35M | -2.49M |
| ChangeInOtherCurrentLiabilities | -654.00K | -578.00K | -878.00K | |
| ChangeInPayablesAndAccruedExpense | -1.05M | -1.97M | 1.46M | -1.70M |
| ChangeInAccruedExpense | -1.19M | -710.00K | 844.00K | |
| ChangeInPayable | 146.00K | -1.26M | 617.00K | -1.70M |
| ChangeInAccountPayable | 146.00K | -1.26M | 617.00K | |
| ChangeInPrepaidAssets | 2.98M | 502.00K | 532.00K | |
| ChangeInReceivables | -1.65M | 456.00K | -3.47M | -794.94K |
| OtherNonCashItems | 3.10M | 1.84M | 2.10M | 18.10M |
| StockBasedCompensation | 7.39M | 4.92M | 4.77M | 4.46M |
| ProvisionandWriteOffofAssets | 255.35K | 1.87M | ||
| AssetImpairmentCharge | 9.46M | |||
| DepreciationAmortizationDepletion | 1.09M | 1.06M | 889.00K | 866.47K |
| DepreciationAndAmortization | 1.09M | 1.06M | 889.00K | 866.47K |
| AmortizationCashFlow | 438.00K | 395.00K | 0.00 | |
| AmortizationOfIntangibles | 438.00K | 395.00K | 0.00 | |
| Depreciation | 650.00K | 666.00K | 889.00K | 866.47K |
| OperatingGainsLosses | -791.00K | 2.10M | -12.01M | -52.90M |
| GainLossOnInvestmentSecurities | 419.00K | -245.00K | -9.29M | -54.04M |
| NetForeignCurrencyExchangeGainLoss | -1.21M | 2.35M | -2.72M | 1.29M |
| GainLossOnSaleOfPPE | 0.00 | -152.51K | ||
| NetIncomeFromContinuingOperations | -43.25M | -29.47M | -42.22M | 19.22M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MREO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|